Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade?
OBJECTIVE
The aim of the present study is to assess whether or not there has been improvement in the therapeutic strategy for body-tail pancreatic carcinoma over the past decade.


METHODS
A total of 215 patients suffering from cytologically and histologically documented ductal carcinoma in the pancreatic body-tail, observed from 1990 to 1999, were analysed. Changes in tumour stage at diagnosis, in the percentage of patients treated surgically, in resectability rates and in the use of anticancer therapies over the years were sought. Survival curves were evaluated in relation to the treatments adopted.


RESULTS
Over the 10-year period, no significant differences were observed with respect to the stage at diagnosis, resectability or type of surgery adopted. There was a significant increase in the percentage of unoperated patients (p < 0.0001) and, as expected, in the percentages of patients submitted to chemo- and/or radiotherapy (p < 0.0001). With the sole exception of tumour stage in the case of patients undergoing radiotherapy, a comparison between groups revealed no element of patient selection bias other than time. The survival of patients undergoing chemotherapy is significantly better, also at multivariate analysis, than that of patients not undergoing such therapy (13 vs. 5.8 months; p < 0.0001).


CONCLUSIONS
There has been no change over the years in the direction of earlier diagnosis and the prognosis remains distinctly poor. More extensive use of anticancer therapies, however, has led to a significant increase in median survival. Radical resection, when possible, assures the longest survival.
Falconi
M
M
Department of Surgery, University of Verona, Verona, Italy. massimo.falconi@univr.it
Mantovani
W
W
Bettini
R
R
Talamini
G
G
Bassi
C
C
Cascinu
S
S
Oliani
C
C
Pederzoli
P
P
D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate